Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 2/20 | 0.68 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.68 |
| ▸ | DRD3 | P35462 | 2/20 | 0.68 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.68 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.66 |
| ▸ | LMNA | P02545 | 3/20 | 0.66 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.64 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.64 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.64 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.64 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.64 |
| ▸ | MC4R | P32245 | 1/20 | 0.60 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | GSK3B | P49841 | 1/20 | 0.47 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lanperisone SCHEMBL5819917 | 1.00 | CHRM2 (0.68) | CHRM2ADRA2BDRD3SIGMAR1HRH3 | |
| Lanperisone SCHEMBL1987393 | 0.99 | ALDH1A1 (0.68) | CHRM2ADRA2BDRD3SIGMAR1HRH3 | |
| Lanperisone SCHEMBL5819985 | 0.99 | ALDH1A1 (0.68) | CHRM2ADRA2BDRD3SIGMAR1HRH3 | |
| SCHEMBL9720545 | 0.99 | CHRM2 (0.70) | CHRM2ADRA2BDRD3SIGMAR1HRH3 | |
| SCHEMBL13058950 | 0.88 | ALDH1A1 (0.67) | CHRM2ADRA2BDRD3SIGMAR1HRH3 | |
| SCHEMBL9168033 | 0.87 | CHRM2 (0.69) | CHRM2ADRA2BDRD3SIGMAR1HRH3 | |
| SCHEMBL10851001 | 0.86 | SIGMAR1 (0.72) | CHRM2ADRA2BDRD3SIGMAR1HRH3 | |
| SCHEMBL17832656 | 0.83 | CHRM2 (0.46) | CHRM2ADRA2BDRD3SIGMAR1HRH3 | |
| Lanperisone SCHEMBL9820433 | 0.83 | CHRM2 (0.60) | CHRM2ADRA2BDRD3SIGMAR1HRH3 | |
| SCHEMBL12123621 | 0.82 | CHRM2 (0.76) | CHRM2ADRA2BDRD3SIGMAR1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 578 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4739299-A1 | MODELS OF CONE PHOTORECEPTOR DEGENERATION | SORBONNE UNIVERSITE (FR) | 2026-05-13 | — | — | EP | claimed |
| EP-4694909-A1 | METHODS OF MODULATING THE EPITHELIAL-MESENCHYMAL TRANSITION | RS Oncology, LLC (US) | 2026-02-18 | — | — | EP | claimed |
| WO-2025012134-A1 | MODELS OF CONE PHOTORECEPTOR DEGENERATION. | SORBONNE UNIVERSITE (FR) | 2025-01-16 | — | — | WO | claimed |
| WO-2025012666-A1 | MODELS OF CONE PHOTORECEPTOR DEGENERATION | SORBONNE UNIVERSITE (FR) | 2025-01-16 | — | — | WO | claimed |
| WO-2024220955-A2 | COMBINING INDUCTION OF FERROPTOSIS WITH TARGETED AGENTS FOR CANCER THERAPY | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2024-10-24 | — | — | WO | claimed |
| WO-2024215577-A1 | METHODS OF MODULATING THE EPITHELIAL-MESENCHYMAL TRANSITION | RS ONCOLOGY, LLC (US) | 2024-10-17 | — | — | WO | claimed |
| US-20240287148-A1 | ENGINEERED BIOMOLECULES FOR NUTRIENT REPROGRAMMING | CORNELL UNIVERSITY | 2024-08-29 | — | — | US | claimed |
| US-20240245680-A1 | Methods of Treating Retinal Vasculopathies | UNITY BIOTECHNOLOGY, INC. | 2024-07-25 | — | — | US | claimed |
| WO-2024145451-A2 | METHODS FOR RESTORING REGENERATIVE POTENTIAL OF AGED LUNG ALVEOLI AND AGED ADULT STEM CELL COMPARTMENTS | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2024-07-04 | — | — | WO | claimed |
| EP-4346813-A1 | METHODS OF TREATING RETINAL VASCULOPATHIES | Unity Biotechnology, Inc. (US) | 2024-04-10 | — | — | EP | claimed |
| WO-2010068467-A1 | IMPLANT WITH HIGH VAPOR PRESSURE MEDIUM | ATTENUEX TECHNOLOGIES, INC. (US) | 2010-06-17 | — | — | WO | claimed |
| CN-101330905-A | Freeze-drying process and products obtained thereby | SCIDOSE LLC (US) | 2008-12-24 | — | — | CN | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| US-20060024365-A1 | Novel dosage form | VAYA NAVIN | 2006-02-02 | — | — | US | claimed |
| US-20060018933-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-20060018934-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| EP-1336602-A1 | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases | Scaramuzzino, Giovanni (IT) | 2003-08-20 | — | — | EP | claimed |
| EP-0770386-B1 | Lanperisone formulation | NIPPON KAYAKU KK (JP) | 2000-02-02 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240287148-A1 | ENGINEERED BIOMOLECULES FOR NUTRIENT REPROGRAMMING | FABP4, GFPT1, IDH2 | CHRM2 4875/4885ADRA2B 4713/4885DRD3 4817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.